These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 23587152)
1. Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach. Abe S; Chiba K; Suwa T Int J Clin Pharmacol Ther; 2013 Jun; 51(6):482-9. PubMed ID: 23587152 [TBL] [Abstract][Full Text] [Related]
2. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369 [TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. Damle B; Jen F; Sherman N; Jani D; Sweeney K J Clin Pharmacol; 2021 Feb; 61(2):172-180. PubMed ID: 32827160 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Stöbe J; Siegemund A; Achenbach H; Preiss C; Preiss R Int J Clin Pharmacol Ther; 2006 Oct; 44(10):455-65. PubMed ID: 17063975 [TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. Schwarzwald CC; Feige K; Wunderli-Allenspach H; Braun U Am J Vet Res; 2002 Jun; 63(6):868-73. PubMed ID: 12061534 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the low molecular weight heparin dalteparin in cats. Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598 [TBL] [Abstract][Full Text] [Related]
7. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Yee JY; Duffull SB Eur J Clin Pharmacol; 2000 Jul; 56(4):293-7. PubMed ID: 10954342 [TBL] [Abstract][Full Text] [Related]
8. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. Schmid P; Brodmann D; Odermatt Y; Fischer AG; Wuillemin WA J Thromb Haemost; 2009 Oct; 7(10):1629-32. PubMed ID: 19624460 [TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blombäck M; Bremme K; Hellgren M; Lindberg H Blood Coagul Fibrinolysis; 1998 Jun; 9(4):343-50. PubMed ID: 9690805 [TBL] [Abstract][Full Text] [Related]
10. Intestinal absorption of low molecular weight heparin in animals and human subjects. Nissan A; Ziv E; Kidron M; Bar-On H; Friedman G; Hyam E; Eldor A Haemostasis; 2000; 30(5):225-32. PubMed ID: 11251329 [TBL] [Abstract][Full Text] [Related]
11. [Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. Grebe S; Jacobs C; Kietzmann M; Mischke R Berl Munch Tierarztl Wochenschr; 2000 Mar; 113(3):103-7. PubMed ID: 10763553 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dalteparin during haemodialysis. Nigten J; de Groot KA; Grootendorst DC; Koolen SL; Herruer MH; Schut NH Nephron Clin Pract; 2013; 124(3-4):179-83. PubMed ID: 24401673 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. Ishida M; Nakada Y; Horiuchi M; Sakamoto F Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709 [TBL] [Abstract][Full Text] [Related]
14. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Brieger D; Dawes J Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589 [TBL] [Abstract][Full Text] [Related]
15. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664 [TBL] [Abstract][Full Text] [Related]
16. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM Crit Care; 2006; 10(3):R93. PubMed ID: 16790078 [TBL] [Abstract][Full Text] [Related]
17. Excretion of low molecular weight heparin in human milk. Richter C; Sitzmann J; Lang P; Weitzel H; Huch A; Huch R Br J Clin Pharmacol; 2001 Dec; 52(6):708-10. PubMed ID: 11736885 [TBL] [Abstract][Full Text] [Related]
18. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M; Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071 [TBL] [Abstract][Full Text] [Related]
20. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. Schmid P; Brodmann D; Fischer AG; Wuillemin WA J Thromb Haemost; 2009 Apr; 7(4):552-8. PubMed ID: 19175499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]